Local Coverage Determination (LCD)

Intravenous Immunoglobulin (IVIG)

L34580

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
Palmetto GBA	A and B MAC	10111 - MAC A	J - J	Alabama
Palmetto GBA	A and B MAC	10112 - MAC B	J - J	Alabama
Palmetto GBA	A and B MAC	10211 - MAC A	J - J	Georgia
Palmetto GBA	A and B MAC	10212 - MAC B	J - J	Georgia
Palmetto GBA	A and B MAC	10311 - MAC A	J - J	Tennessee
Palmetto GBA	A and B MAC	10312 - MAC B	J - J	Tennessee
Palmetto GBA	A and B and HHH MAC	11201 - MAC A	J - M	South Carolina
Palmetto GBA	A and B and HHH MAC	11202 - MAC B	J - M	South Carolina
Palmetto GBA	A and B and HHH MAC	11301 - MAC A	J - M	Virginia
Palmetto GBA	A and B and HHH MAC	11302 - MAC B	J - M	Virginia
Palmetto GBA	A and B and HHH MAC	11401 - MAC A	J - M	West Virginia
Palmetto GBA	A and B and HHH MAC	11402 - MAC B	J - M	West Virginia
Palmetto GBA	A and B and HHH MAC	11501 - MAC A	J - M	North Carolina
Palmetto GBA	A and B and HHH MAC	11502 - MAC B	J - M	North Carolina

LCD Information

Document Information

LCD ID
L34580

LCD Title
Intravenous Immunoglobulin (IVIG)

Proposed LCD in Comment Period
N/A

Source Proposed LCD
DL34580

Original Effective Date
For services performed on or after 10/01/2015

Revision Effective Date
For services performed on or after 04/04/2024

Revision Ending Date
N/A

Retirement Date
N/A

Notice Period Start Date
08/20/2020

Notice Period End Date
10/03/2020

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Issue

Issue Description

This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity.

CMS National Coverage Policy

Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

42 CFR §411.15(a) and (k) Particular services excluded from coverage.

CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 6, §20.5.1 Coverage of Outpatient Therapeutic Services Incident to a Physician’s Service Furnished on or After August 1, 2000, and Before January 1, 2010.

CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 8, §50.5 Drugs and Biologicals.

CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 13, §110 Physician Services and §120 Services and Supplies Furnished “Incident to” Physician’s Services.

CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §50 Drugs and Biologicals, §50.1 Definition of Drug or Biological, §50.2 Determining Self-Administration of Drug or Biological, §50.3 Incident To Requirements, §50.4.1 Approved Use of Drug, §50.4.2 Unlabeled Use of Drug, §50.4.3 Examples of Not Reasonable and Necessary, §50.4.5 Off-Label Use of Drugs and Biologicals in an Anti-Cancer Chemotherapeutic Regimen, §50.4.6 Less Than Effective Drug, and §200 Nurse Practitioner (NP) Services.

CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 4, §250.3 Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Intravenous Immune Globulin (IVIG) is a solution of human immunoglobulins specifically prepared for intravenous infusion. Immunoglobulins contain a broad range of antibodies that act specifically against bacterial and viral antigens.

INDICATIONS:

Treatment of primary immunodeficiency syndromes associated with defects in humoral immunity to replace or boost immunoglobulin G (IgG)
Treatment of idiopathic thrombocytopenic purpura (ITP) when a rapid rise in the platelet count is required such as prior to surgery, to control excessive bleeding, or to defer or avoid splenectomy
Treatment of Kawasaki disease, in conjunction with aspirin
Prevention of recurrent bacterial infections in patients with hypogammaglobulinemia associated with B-cell chronic lymphocytic leukemia (CLL)
Decreasing risk of acute graft versus host disease, associated interstitial pneumonia, and infections after bone marrow transplant in the first 100 days after transplantation
Reducing the risk of severe bacterial infections in human immunodeficiency virus (HIV) infected children with a CD4 count of greater than 200 to 400
Second-line treatment of certain autoimmune myopathies
Treatment of adults with Guillain-Barré syndrome diagnosed within the first 2 weeks of illness
Treatment of hyperimmunoglobulinemia E syndrome and Lambert-Eaton myasthenic syndrome (LEMS)
Treatment of multifocal motor neuropathy (MMN)
Treatment of relapsing-remitting multiple sclerosis
Treatment of chronic parvovirus B19 infection and severe anemia associated with bone marrow suppression and pure red cell aplasia
Treatment of progressive pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa acquisita in patients that have failed conventional treatment and patients in whom conventional therapy is otherwise contraindicated
For coverage criteria of autoimmune mucocutaneous blistering diseases, please see CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations Manual, Chapter 1, Part 4, §250.3
Treatment of stiff person syndrome
Treatment of myasthenia gravis (MG) in patients who have profound, rapidly progressive and/or potentially life-threatening muscular weakness and are refractory to, or intolerant of cholinesterase inhibitors, corticosteroids and azathioprine
Prevention and/or treatment of organ rejection in patients sensitized to living or cadaveric organ donors
Schonlein-Henoch
Treatment of paraneoplastic visual loss
Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in patients meeting the necessary criteria
Treatment of multiple myeloma for the prevention of life-threatening infections due to reduced gamma globulins

Summary of Evidence

IVIG has been used for many years in the treatment of immunodeficiency disease. As the knowledge of these diseases has improved and expanded, the use of IVIG has proportionally grown. With this, the body of literature supporting the use of IVIG in these situations has equally grown. The literature supports the use of IVIG in acute situations such as prevention of infections in patients with solid organ and bone marrow transplants, myeloma, leukemia, and HIV infections as well as in the acquired and genetic immunodeficiency syndromes such as CIDP. Additionally, the use in blocking damage by toxic antibodies in Guillain-Barré syndrome, pemphigus and its variants has been shown to be effective.

Analysis of Evidence (Rationale for Determination)

IVIG is an important adjunct or primary treatment in multiple situations where immunoglobulin abnormalities cause complications because of decreased or toxic antibodies. As shown in the Bibliography, there is a significant literature base to support its use in these situations. This contractor will continue to monitor the literature for additional uses of IVIG as they develop.

Proposed Process Information

Synopsis of Changes

Changes	Fields Changed
	N/A

Associated Information

Sources of Information

Bibliography

Open Meetings

Contractor Advisory Committee (CAC) Meetings

MAC Meeting Information URLs

Proposed LCD Posting Date

Comment Period Start Date

Comment Period End Date

Reason for Proposed LCD

Requestor Name	Requestor Letter
	View Letter

Requestor Information

Contact for Comments on Proposed LCD

Coding Information

ICD-10-CM Codes that Support Medical Necessity

ICD-10-CM Codes that DO NOT Support Medical Necessity

Additional ICD-10 Information

General Information

Associated Information

Documentation Requirements

Documentation supporting the medical necessity should be legible, maintained in the patient's medical record, and must be made available to the A/B MAC upon request.

Utilization Guidelines

Paraneoplastic visual loss is an autoimmune disorder believed to be caused by the remote effects of cancer on the retina (cancer associated retinopathy (CARI) or optic nerve). Research has shown that the use of intravenous immunoglobulins for paraneoplastic visual loss would be another treatment option.

Sources of Information

N/A

Bibliography

Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfusion Medicine Reviews. 2007;21(2 Suppl 1):S9-S56.
Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurol. 1996;47:678-683.
Balasubramanian SK, Sadaps M, Thota S, et al. Rational management approach to pure red cell aplasia. Haematologica. 2018;103(2):221-230.
Chapel HM, Lee M. The use of intravenous immune globulin in multiple myeloma. Clin Exp Immunol. 1994;97(Suppl 1):21–24.
Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: A retrospective study of 10 patients and review of the literature. Clinical Infectious Diseases. 2013;56(7):968-977.
Donofrio PD, Berger A, Brannagan TH III, et al. Consensus statement: The use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve. 2009;40(5):890-900.
Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur Jour of Neurol. 2008;15(9):893-908.
Gammaked™. Grifols Therapeutics; 2018. Accessed 2/27/24.
Gamunex^®-C. Grifols Therapeutics; 2020. Accessed 2/27/24.
Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: Report of 3 cases. Arch Ophthalmol. 1999;117(4):471-477.
John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation. 1999;100(19 Suppl):II229-II235.
Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Trans. 2011;11(2):196-202.
Khalafallah A, Maiwald M, Cox A, et al. Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents. Medit J Hemat Infect Dis. 2010;2(1):Open Journal System.
Kim IK, Vo A, Jordan SC. Transplantation in highly HLA-sensitized patients: Challenges and solutions. Transplant Research and Risk Management. 2014;6:99-107.
Latov N. Diagnosis of CIDP. Neurol. 2002;59(12 Suppl 6):S2-S6.
Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: The use of plasmapheresis and intravenous immunoglobulin. Clin Transplant. 2006;20(4):476-484.
National Institute for Health and Clinical Excellence. Multiple sclerosis: Management of multiple sclerosis in primary and secondary care. NICE; 2014.
National Comprehensive Cancer Network^®, NCCN^® Guidelines: Multiple Myeloma. Version 1. 2020.
Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4):S525-S553.
Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurol. 2012;78(13):1009-1015.
Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18(7):701-706.
Kyle RA, Rajkumar SV. Treatment of multiple myeloma: A comprehensive review. Clin Lymphoma Myeloma. 2009;9(4):278–288.
Ross MA. Intravenous immunoglobulin therapy for neuromuscular disorders. Seminars in Neurol. 2007;27(4):340-346.
Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: A prospective study. Neurol. 2010;74(21):1680-1686.
Sander HW, Latov N. Research criteria for defining patients with CIDP. Neurol. 2003;60(Suppl 3):S8-S15.
The United States Pharmacopeia Drug Information (USPDI): Drug Information for the Health Care Professional. 26th ed. Greenwood Village, CO: Thomson Micromedex. 2006:1714-1720.
U.S. Food and Drug Administration (FDA). Immune Globulin Intravenous (IGIV) Indications. Accessed 2/27/24.
Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol. 2010;17(3):356-363.
Van Schaik IN, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review. Lancet Neurology. 2002;1(8):491-498.
Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018;36(2):379-394.

Revision History Information

Revision History Date	Revision History Number	Revision History Explanation	Reasons for Change
04/04/2024	R22	Under *CMS National Coverage Policy* revised second regulation to read “42 CFR §411.15(a) and (k) Particular services excluded from coverage”. Under *Bibliography* fixed broken hyperlink on reference #8 and changes were made to citations to reflect AMA citation guidelines.	Provider Education/Guidance
05/18/2023	R21	Under *CMS National Coverage Policy* section headings were updated. Under *Coverage Indications, Limitations and/or Medical Necessity* broken hyperlink was fixed. Under *Bibliography* changes were made to citations to reflect AMA citation guidelines and fixed broken hyperlink for reference #27. Punctuation and typographical errors were corrected throughout the LCD.	Provider Education/Guidance
07/07/2022	R20	Under *CMS National Coverage Policy* updated section headings for regulations. Under *Coverage Indications, Limitations and/or Medical Necessity* *– Indications* revised seventh bullet to read “Second-line treatment of certain autoimmune myopathies”.	Provider Education/Guidance
10/04/2020	R19	This LCD is being presented for notice. No comments were received during the comment period; therefore, no changes have been made. At this time 21^stCentury Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Provider Education/Guidance
10/10/2019	R18	This LCD is being revised in order to adhere to CMS requirements per chapter 13, section 13.5.1 of the Program Integrity Manual, to remove all coding from LCDs. There has been no change in coverage with this LCD revision. Regulations regarding billing and coding were removed from the *CMS National Coverage Policy* section of this LCD and placed in the related Billing and Coding: Intravenous Immunoglobulin (IVIG) A56718 article. At this time 21^stCentury Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Provider Education/Guidance
07/25/2019	R17	All coding located in the *Coding Information* section and all verbiage regarding billing and coding under the *Associated Information* section has been removed and is included in the related Billing and Coding: Intravenous Immunoglobulin (IVIG) A56718 article. At this time 21^stCentury Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Provider Education/Guidance
07/04/2019	R16	Under *Bibliography* changes were made to citations to reflect AMA citation guidelines. Formatting, punctuation and typographical errors were corrected throughout the LCD. Acronyms were inserted where appropriate throughout the LCD. At this time 21^stCentury Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Provider Education/Guidance
07/26/2018	R15	Under Coverage Indications, Limitations and/or Medical Necessity Initial Treatment revised the first sentence to now read “Diagnosis of chronic inflammatory demyelinating polyneuropathy as confirmed by all of the following (a through c):” Under Coverage Indications, Limitations and/or Medical Necessity Initial Treatment “d” the verbiage was changed from “BOTH of the following findings on lumbar puncture18 i.White blood cell count less than 10/mm3” to now read “The following findings on lumbar puncture are not absolutely required but may support the diagnosis:18”. This revision is due to a reconsideration request. At this time 21^stCentury Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Reconsideration Request
05/31/2018	R14	Under *CMS National Coverage Policy* changed verbiage to now read “describes payment for services that may be furnished to a practitioner. Requests for payment, or bills submitted shall include the appropriate diagnosis code(s)” in the third regulation. The verbiage was changed from “must be reasonable and necessary” to now read “excluded from coverage” in the fourth regulation. The last two regulations were deleted from this section. Under *Coverage Indications, Limitations and/or Medical Necessity - A. Initial treatment* added the verbiage “American Academy of Neurology” in front of the acronym “AAN” and placed parentheses around the acronym. Under *Bibliography* changes were made to citations to reflect AMA citation guidelines. The initials of the third author was corrected to now read “van Doorn P” in the third reference. The reference date was changed from 2008 to 2014 in the fifth reference. The link was deleted and the title has changed to now read “Multiple sclerosis: management of multiple sclerosis in primary and secondary care. NICE; 2014” in the ninth reference. The access date was changed to May 21, 2018 in the sixteenth reference. Punctuation and typographical errors were corrected throughout the policy. At this time 21^stCentury Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Provider Education/Guidance Typographical Error
02/26/2018	R13	The Jurisdiction "J" Part B Contracts for Alabama (10112), Georgia (10212) and Tennessee (10312) are now being serviced by Palmetto GBA. The notice period for this LCD begins on 12/14/17 and ends on 02/25/18. Effective 02/26/18, these three contract numbers are being added to this LCD. No coverage, coding or other substantive changes (beyond the addition of the 3 Part B contract numbers) have been completed in this revision.	Change in Affiliated Contract Numbers
01/29/2018	R12	The Jurisdiction "J" Part A Contracts for Alabama (10111), Georgia (10211) and Tennessee (10311) are now being serviced by Palmetto GBA. The notice period for this LCD begins on 12/14/17 and ends on 01/28/18. Effective 01/29/18, these three contract numbers are being added to this LCD. No coverage, coding or other substantive changes (beyond the addition of the 3 Part A contract numbers) have been completed in this revision.	Change in Affiliated Contract Numbers
12/14/2017	R11	Under CMS National Coverage Policy added CMS Internet-Only Manual, Pub 100-02, Medicare Benefit Policy Manual, Chapter 15, §50.4.6; Less Than Effective Drug.	Provider Education/Guidance
10/01/2017	R10	Under *ICD-10 Codes That Support Medical Necessity* added ICD-10 codes M33.03, M33.13 and M33.93. The code description was revised for M33.00, M33.01, M33.02, M33.09, M33.10, M33.11, M33.12 and M33.19. This revision is due to the 2017 Annual ICD-10 Updates. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Provider Education/Guidance Revisions Due To ICD-10-CM Code Changes
04/03/2017	R9	Under *ICD-10 Codes That Support Medical Necessity Group 1: Codes* added G61.82.	Provider Education/Guidance Reconsideration Request
07/07/2016	R8	This LCD is being made an A/B MAC LCD. No coverage changes were made.	Provider Education/Guidance Creation of Uniform LCDs Within a MAC Jurisdiction
01/04/2016	R7	The description changed for HCPCS codes J1459, J1557, J1561, J1566, J1568, J1569, J1572 and J1599 under the CPT/HCPCS Codes section.	Revisions Due To CPT/HCPCS Code Changes
01/04/2016	R6	Under Coverage Indications, Limitations and/or Medical Necessity added verbiage "for coverage criteria of Autoimmune Mucocutaneous Blistering Diseases, please see NCD 250.3". Under ICD-10 Codes that Support Medical Necessity added L10.0, L10.1, L10.2, L10.3, L10.4, L10.5, L10.81, L10.89, L10.9, L12.0, L12.1, L12.8, L12.9, L13.8 for reference. Under ICD-10 Codes that DO NOT Support Medical Necessity removed NOTE: as per CR 9252 Transmittal 1547 the bullous conditions are no longer covered effective January 4, 2016 as coverage for these codes is under NCD 250.3.	Provider Education/Guidance NCD Supplementation Typographical Error
01/04/2016	R5	Under CMS National Coverage Policy added reference to Change Request 9252 Transmittal 1547. Under Coverage Indications, Limitations and/or Medical Necessity created a new section titled Off-label Indication, and added off-label coverage for Livedoid Vasculitis and Livedoid Vasculopathy for patients who are refractory to or have failed conventional therapies. Under ICD-10 Codes that Support Medical Necessity removed L10.0-L13.8 as per CR 9252 Transmittal 1547 NCD 250.3 (these codes are no longer valid for processing Medicare claims) and added off-label coverage for L95.0 and L95.9. Under ICD-10 Codes that DO NOT Support Medical Necessity added L10.0-L13.8 as per CR 9252 Transmittal 1547 the bullous conditions are no longer covered.	Provider Education/Guidance Public Education/Guidance Request for Coverage by a Provider (Part A) Reconsideration Request Other (Change Request 9252 updated NCD 250.3)
10/29/2015	R4	Under Coverage Indications, Limitations and/or Medical Necessity formatting changes were made. Under Associated Information, sub-heading Utilization Guidelines 2nd paragraph added a space between (CARI) and the word "or". Under Sources of Information and Basis for Decision added the assess dates the web-sited were reviewed.	Provider Education/Guidance
10/01/2015	R3	Under Coverage Indications, Limitations and/or Medical Necessity added updated coverage criteria for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Under Revenue Codes removed the statement "Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes" as all revenue codes have been removed from policies. Under ICD-10 Codes that Support Medical Necessity removed L14 per NCD 250.3. Under Sources of Information and Basis for Decision added sources for CIDP coverage.	Provider Education/Guidance Reconsideration Request Other (Per CR 9252 NCD 250.3 removed L14. )
10/01/2015	R2	In Coverage Indications, Limitations and/or Medical Necessity made punctuation corrections. In Associated Information corrected Paraneoplastic spelling, removed “This is very rare” and added the sentence “Research has shown that the use of intravenous immunoglobulins for Paraneoplastic Visual Loss would be another treatment option.”	Provider Education/Guidance Other (Annual Validation)
10/01/2015	R1	Under *CMS National Coverage Policy* removed a section from Publication 100-02, Chapter 15, section 50.2 as this reference was specific to Self-Administered Drugs and IVIG would never be self-administered.	Provider Education/Guidance

Associated Documents

Attachments
N/A

Updated On	Effective Dates	Status
03/28/2024	04/04/2024 - N/A	Currently in Effect	You are here
05/08/2023	05/18/2023 - 04/03/2024	Superseded	View
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

IVIG
Intravenous Immunoglobulin

Read the LCD Disclaimer

Please review and accept the agreements in order to view Medicare Coverage documents, which may include licensed information and codes.

LICENSE FOR USE OF PHYSICIANS' CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION ("CPT")

End User Point and Click Amendment:

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

AMA Disclaimer of Warranties and Liabilities.

CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

CMS Disclaimer

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled "I Accept".

LICENSE FOR USE OF CURRENT DENTAL TERMINOLOGY (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org.
Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use. U.S. Government Rights Provisions.
Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.
ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement.

The ADA is a third party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Intravenous Immunoglobulin (IVIG)

Document Note

Note History

Contractor Information

LCD Information

Document Information

Issue

CMS National Coverage Policy

Coverage Guidance

Proposed Process Information

Coding Information

Bill Type Codes

Revenue Codes

CPT/HCPCS Codes

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Additional ICD-10 Information

General Information

Revision History Information

Associated Documents

Keywords

Page Help for LCD - Intravenous Immunoglobulin (IVIG) (L34580)

Introduction

More information

Tracking Sheet

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS